Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aclaris Therapeutics, Inc. (ACRS)

Aclaris reports Phase 1b ATI-052 trial results in atopic dermatitis and asthma

Positive Impact 4 of 5 other Written later

Aclaris Therapeutics reported primary analysis results from two small Phase 1b proof-of-concept trials of its bispecific antibody ATI-052, in atopic dermatitis (14 patients) and asthma (16 patients). The company also estimated unaudited cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026, and said it will prioritize development in eosinophilic esophagitis with a Phase 2b trial planned for early 2027.

Key points

  • Atopic dermatitis trial: 45% placebo-adjusted mean EASI improvement at day 57, from a per-protocol population of nine active-arm and one placebo-arm patient
  • Asthma trial: 59% mean FeNO reduction at day 15 in the ATI-052 arm versus 15% in the placebo arm, with 16 patients enrolled
  • Estimated cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026; figure is unaudited and may change
  • Company plans to start a Phase 2b trial in eosinophilic esophagitis in early 2027

The filing

CompanyAclaris Therapeutics, Inc. (ACRS)
Form8-K, current report
Filed with the SECOct 27, 2026, 6:06 AM ET
Accession number0001104659-26-118952

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.